New acetylcholinesterase inhibitors for Alzheimer's disease
- PMID: 22216416
- PMCID: PMC3246720
- DOI: 10.1155/2012/728983
New acetylcholinesterase inhibitors for Alzheimer's disease
Abstract
Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds.
Similar articles
-
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.Curr Pharm Des. 2019;25(33):3519-3535. doi: 10.2174/1381612825666191008103141. Curr Pharm Des. 2019. PMID: 31593530 Review.
-
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.J Alzheimers Dis. 2014;39(2):423-40. doi: 10.3233/JAD-130845. J Alzheimers Dis. 2014. PMID: 24217282 Clinical Trial.
-
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer's Disease.Brain Sci. 2021 Feb 2;11(2):184. doi: 10.3390/brainsci11020184. Brain Sci. 2021. PMID: 33540879 Free PMC article.
-
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.Drug Saf. 1998 Dec;19(6):465-80. doi: 10.2165/00002018-199819060-00004. Drug Saf. 1998. PMID: 9880090 Review.
-
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.Int J Clin Pract Suppl. 2002 Jun;(127):45-63. Int J Clin Pract Suppl. 2002. PMID: 12139367 Review.
Cited by
-
The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.J Psychiatry Neurosci. 2017 Jan;42(1):59-69. doi: 10.1503/jpn.150209. J Psychiatry Neurosci. 2017. PMID: 27636528 Free PMC article.
-
Phytochemical Screening of Rosmarinus officinalis L. as a Potential Anticholinesterase and Antioxidant-Medicinal Plant for Cognitive Decline Disorders.Plants (Basel). 2022 Feb 14;11(4):514. doi: 10.3390/plants11040514. Plants (Basel). 2022. PMID: 35214846 Free PMC article.
-
Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.Bioorg Med Chem Lett. 2019 Dec 15;29(24):126754. doi: 10.1016/j.bmcl.2019.126754. Epub 2019 Oct 28. Bioorg Med Chem Lett. 2019. PMID: 31708262 Free PMC article.
-
Lipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route.Pharmaceuticals (Basel). 2022 Feb 24;15(3):281. doi: 10.3390/ph15030281. Pharmaceuticals (Basel). 2022. PMID: 35337079 Free PMC article.
-
Vitisin A, a Resveratrol Tetramer, Improves Scopolamine-Induced Impaired Learning and Memory Functions in Amnesiac ICR Mice.Biomedicines. 2022 Jan 26;10(2):273. doi: 10.3390/biomedicines10020273. Biomedicines. 2022. PMID: 35203483 Free PMC article.
References
-
- Orhan G, Orhan I, Öztekin-Subutay N, Ak F, Şener B. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer’s disease. Recent Patents on CNS Drug Discovery. 2009;4(1):43–51. - PubMed
-
- Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer’s disease. Current Medicinal Chemistry. 2010;17(17):1825–1838. - PubMed
-
- Fernández-Bachiller MI, Pérez C, González-Muñoz GC, et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimers disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. Journal of Medicinal Chemistry. 2010;53(13):4927–4937. - PubMed
-
- Tacrine. Drugs in Clinical Trials. Alzheimer Research Forum, http://www.alzforum.org/drg/drc/detail.asp?id=90.
-
- Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine. 1998;158(9):1021–1031. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources